Shanghai RAAS Blood Products Co Ltd Class A (002252) — Working Capital to Net Assets Ratio
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Working Capital to Net Assets ratio of 23.4% as of March 2026. Working capital of CN¥7.61 Billion (current assets of CN¥10.40 Billion minus current liabilities of CN¥2.79 Billion) is measured against net assets of CN¥32.52 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Shanghai RAAS Blood Products Co Ltd Clas to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai RAAS Blood Products Co Ltd Class A Working Capital to Net Assets (2005–2025)
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Working Capital to Net Assets ratio has evolved across 21 annual periods from 2005 to 2025. As of March 2026, the ratio stands at 23.4%, reflecting working capital of CN¥7.61 Billion against net assets of CN¥32.52 Billion CNY. See Shanghai RAAS Blood Products Co Ltd Clas (002252) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025, covering 21 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Shanghai RAAS Blood Products Co Ltd Clas market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 22.2% | CN¥7.21 Billion | CN¥32.47 Billion | CN¥9.95 Billion | CN¥2.74 Billion | ▼ -1.6 pp |
| 2024 | 23.8% | CN¥7.61 Billion | CN¥31.94 Billion | CN¥9.26 Billion | CN¥1.65 Billion | ▲ +2.1 pp |
| 2023 | 21.7% | CN¥6.43 Billion | CN¥29.65 Billion | CN¥8.68 Billion | CN¥2.24 Billion | ▼ -2.1 pp |
| 2022 | 23.8% | CN¥6.85 Billion | CN¥28.81 Billion | CN¥8.47 Billion | CN¥1.62 Billion | ▲ +2.3 pp |
| 2021 | 21.5% | CN¥5.57 Billion | CN¥25.90 Billion | CN¥6.87 Billion | CN¥1.31 Billion | ▲ +2.9 pp |
| 2020 | 18.6% | CN¥4.68 Billion | CN¥25.13 Billion | CN¥5.01 Billion | CN¥330.24 Million | ▼ -18.1 pp |
| 2019 | 36.7% | CN¥4.22 Billion | CN¥11.49 Billion | CN¥4.53 Billion | CN¥309.40 Million | ▲ +4.7 pp |
| 2018 | 32.0% | CN¥3.49 Billion | CN¥10.90 Billion | CN¥3.91 Billion | CN¥424.60 Million | ▼ -18.3 pp |
| 2017 | 50.3% | CN¥6.27 Billion | CN¥12.48 Billion | CN¥6.94 Billion | CN¥663.86 Million | ▲ +5.9 pp |
| 2016 | 44.3% | CN¥5.20 Billion | CN¥11.73 Billion | CN¥6.07 Billion | CN¥871.32 Million | ▲ +1.8 pp |
| 2015 | 42.6% | CN¥4.56 Billion | CN¥10.71 Billion | CN¥4.81 Billion | CN¥246.99 Million | ▲ +15.4 pp |
| 2014 | 27.2% | CN¥2.34 Billion | CN¥8.62 Billion | CN¥2.67 Billion | CN¥324.71 Million | ▼ -46.0 pp |
| 2013 | 73.2% | CN¥806.33 Million | CN¥1.10 Billion | CN¥896.48 Million | CN¥90.15 Million | ▲ +25.2 pp |
| 2012 | 47.9% | CN¥488.73 Million | CN¥1.02 Billion | CN¥650.17 Million | CN¥161.44 Million | ▼ -10.8 pp |
| 2011 | 58.7% | CN¥544.65 Million | CN¥927.27 Million | CN¥614.00 Million | CN¥69.35 Million | ▼ -11.8 pp |
| 2010 | 70.6% | CN¥586.61 Million | CN¥831.21 Million | CN¥674.23 Million | CN¥87.62 Million | ▼ -9.6 pp |
| 2009 | 80.2% | CN¥611.85 Million | CN¥763.33 Million | CN¥663.73 Million | CN¥51.88 Million | ▼ -4.5 pp |
| 2008 | 84.7% | CN¥639.22 Million | CN¥754.76 Million | CN¥715.65 Million | CN¥76.42 Million | ▲ +47.4 pp |
| 2007 | 37.2% | CN¥63.32 Million | CN¥170.01 Million | CN¥199.85 Million | CN¥136.53 Million | ▼ -2.4 pp |
| 2006 | 39.6% | CN¥62.12 Million | CN¥156.77 Million | CN¥230.51 Million | CN¥168.39 Million | ▼ -22.6 pp |
| 2005 | 62.3% | CN¥144.25 Million | CN¥231.70 Million | CN¥246.18 Million | CN¥101.93 Million | — |